I am faithful long IPIX investor and I believe thi
Post# of 72440
I think K was put on back burner for a while and company , very wisely is concentrating on B and P
My big winning horse is B but P has enourmous potentials as well
In my opinion B doesn't need phase III data to be FDA approved.
In long FDA history ,many drugs got approval based on phase II or QoL data ,if there is not a standard of treatment .No control group nor standard of care in case of OM treatment and could be fatal condition so BTD fits perfectly and FDA full approval can follow. this is based on my 25 years experience in this medical field
This is all my opinion only
GLTA